Regeneus enters 2017 backed by transformational Japan deal

Regeneus (ASX:RGS) has a busy 2017 to come, spearheaded by its recent entry into the Japanese market for its Progenza product.

The company entered into a strategic collaboration and licensing agreement for the manufacture, clinical development and commercialisation of Progenza in Japan.

Read the full article by Proactive Investors here.

Regeneus Q4 2016 News Update

Regeneus released our Q4 2016 update newsletter designed to keep our investors and followers of the company up to date with all the company and industry news over the last quarter.

Read our Q4 2017 newsletter here.